Sepracor, MedPointe To End Astelin Co-Promotion Agreement
This article was originally published in The Pink Sheet Daily
Executive Summary
The companies will continue to detail the product until June 30, then Sepracor will be responsible for sample coverage until the end of the year. Sepracor plans to focus sales efforts on in-house products.